Navigation Links
Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies
Date:2/21/2012

13 potentially resulting in key human pharmacokinetic data validating Xtend technology.

About Xencor, Inc.

Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader in the field of antibody engineering to significantly improve antibody half-life, immune-regulatory function and potency. The company is advancing multiple XmAb® antibody drug candidates in the clinic, including XmAb®5871 targeting CD32b and CD19 for autoimmune diseases, and an anti-CD30 candidate XmAb®2513 for the treatment of Hodgkin's lymphoma. Xencor is also advancing a portfolio of biosuperior versions of blockbuster antibody drugs engineered for superior half-life and dosing schedule. Xencor has entered into multiple partnerships with industry leaders such as Amgen, Pfizer, Centocor, MorphoSys, Boehringer Ingelheim, CSL Ltd. and Human Genome Sciences. In these partnerships Xencor is applying its suite of proprietary antibody Fc domains to improve antibody drug candidates for traits such as sustained half-life and/or potency. For more information, please visit www.xencor.com.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Today, Boehringer Ingelheim is one of the world's leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer
'/>"/>

SOURCE Xencor, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CompleGen Announces Successful Delivery of Its XenoGene™ Technology to Boehringer Ingelheim for Drug Discovery Under a Non-Exclusive Agreement.
2. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
3. Boehringer Ingelheim Invests More Than $350 Million in 2011 U.S. Expansion Projects
4. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
5. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
6. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
7. Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
8. Boehringer Ingelheim and Ashokas Changemakers Launch "Making More Health" Competition
9. Ashoka and Boehringer Ingelheim Announce a Global Partnership for "Making More Health"
10. Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
11. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015 RadiologyAuction will have ... live video and product demonstrations at the end of ... equipment such as Kodak and Fuji Cr,s, Agfa and ... at the first event. Various imaging equipment will be ... . After years of buying and selling ...
(Date:5/4/2015)... DOYLESTOWN, Pa. , May 4, 2015  Makindus, ... announced today that the European Medicines Agency (EMA) has ... for the treatment of Stargardt,s Disease. "We ... for MI-100 to treat Stargardt,s disease in place for ... our development program in the United States ...
(Date:5/4/2015)... 2015   HeartWare International, Inc . (NASDAQ: HTWR ... technologies that are revolutionizing the treatment of advanced heart failure, ... is scheduled to present at the Bank of America Merrill ... on Thursday, May 14, 2015, at 10:00 a.m. ... the Company,s presentation at the conference will be available via ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2
... Pharmaceuticals Corporation (the "Company") (OTCQX:RXPC), a developer and marketer ... cancer test, announced that all of the holders of ... compelled by the terms thereof, for 50,000 shares of ... the aggregate. The aggregate exercise price for all of ...
... SILVER SPRING, Md., Nov. 30, 2011 The U.S. ... version of the cholesterol-lowering drug Lipitor (atorvastatin calcium tablets). ... Ranbaxy Laboratories Ltd. has gained approval to make generic ... mg, and 80 mg strengths. The drug will be ...
Cached Medicine Technology:Radient Pharmaceuticals Corporation Receives $500,000 in New Capital 2Radient Pharmaceuticals Corporation Receives $500,000 in New Capital 3FDA Approves First Generic Version of Cholesterol-Lowering Drug Lipitor 2FDA Approves First Generic Version of Cholesterol-Lowering Drug Lipitor 3
(Date:5/4/2015)... 2015 Ticket Down is a reputable source ... Arena in Columbia, South Carolina. Fans of Paul ... “Out There” tour which originally kicked off in 2013. The ... America and the legendary performer recently announced that he would ... Arena on June 21st, in Charlottesville, VA at John Paul ...
(Date:5/4/2015)... CCL, a top-ranked, global provider of leadership ... other leadership development consultancies. “The CCL Partner Network ... practitioners, expanding our capacity to drive results for individual ... Ryan, CCL President and CEO. , As soon as ... , it will schedule a one-on-one conference with a ...
(Date:5/4/2015)... 04, 2015 San Diego Fertility ... at their brand new, 13,700 square foot facility scheduled ... building will not only provide fertility treatment and services ... offer community and educational events to a number of ... located next door to their current Carmel Valley/Del Mar ...
(Date:5/4/2015)... 2015 Dr. Benjamin Stong of Kalos ... the latest non-surgical double-chin eliminator. Dr. Stong is ... in Atlanta to offer Kybella treatments . The ... specifically under the chin, promising to safely dissolve fat ... patients who sought immediate solutions for their double chin ...
(Date:5/4/2015)... Unlike some camps, the Nike Middle School Running Camps are ... to educate first and train second, with a significant amount of ... runners are building the knowledge base needed to have a long ... include Effort Based Training, Running Heroes, Running Vocabulary, and Why am ... is not a camp where kids come to run and train ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2
... URBANA Could preventing colon cancer be as simple as ... University of Illinois study, scientists showed that human colon cancer ... of bioactive compounds present in one cup of this brew, ... medicinal properties. "The caffeine derivatives in mate tea not ...
... of Nebraska-Lincoln will lead a $25 million project to reduce ... coli strains that pose a major threat to public ... Food and Agriculture announced the grant at UNL on Monday, ... coli , or STEC, which cause more than 265,000 illnesses ...
... -- A Kansas State University professor is turning to nutrition ... human nutrition, is helping men make more informed diet decisions ... risk of prostate cancer. Prostate cancer is one of the ... States. "I,m interested in researching ways to prevent prostate ...
... regions of the genome associated with the timing of menopause. ... reproductive lifespan and will provide insights into conditions connected to ... Menopause is a major hormonal change that affects most ... of menopause can have a huge impact on fertility, as ...
... , FRIDAY, Jan. 20 (HealthDay News) -- The number of ... definition of the disorder is adopted by mental health experts ... of the changes will be, but they agree there will ... and the professionals who treat them. The changes could affect ...
... in younger patients treated for breast cancer is seriously ... infertility, premature menopause, a decrease in physical activity and ... UCLA,s Jonsson Comprehensive Cancer Center. , The study, published ... Institute , found that the mental issues faced by ...
Cached Medicine News:Health News:Compounds in mate tea induce death in colon cancer cells 2Health News:U. of Nebraska to lead $25 million project targeting E. coli threat 2Health News:U. of Nebraska to lead $25 million project targeting E. coli threat 3Health News:Eating smart: Researcher studies foods, dietary supplements that may reduce risk of prostate cancer 2Health News:Genes and timing of menopause 2Health News:Experts Weigh Changes to Definition of Autism 2Health News:Experts Weigh Changes to Definition of Autism 3Health News:Quality of life for younger breast cancer patients more adversely affected than older women 2Health News:Quality of life for younger breast cancer patients more adversely affected than older women 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: